★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
Thermo Fisher Scientific Inc. (TMO) Moat Analysis
Thermo Fisher Scientific Inc.
TMO · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Thermo Fisher directly lists NYSE:TMO common stock rather than an ADR; 369,747,286 shares were outstanding on June 27, 2026. Q2 external-revenue mix was 19.6% Life Sciences, 15.0% Analytical Instruments, 9.9% Specialty Diagnostics and 55.5% Laboratory Products/Biopharma Services. The defensible mechanisms are moderate instrument-linked consumables and an embedded laboratory procurement channel; broad brands, a large sales force, regulation and service scope are not independently scored as moats. Clario increased clinical-research exposure, while the pending microbiology sale will narrow diagnostics. Customer budget/capex cycles, dual sourcing, technological obsolescence, China localization, integration risk and competitive procurement remain material. Debt was $42.55bn versus $4.06bn cash after the Clario purchase. CIK, ISIN, CUSIP and active LEI were verified.
Primary segment
Laboratory Products and Biopharma Services
Market structure
Competitive
Market share
—
HHI: —
Coverage
4 segments · 7 tags
Updated 2026-08-23
Segments
Life Sciences Solutions
Life science research tools and bioprocessing consumables/instruments
Revenue
19.6%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Analytical Instruments
Analytical instruments (chromatography, mass spectrometry, electron microscopy) with consumables and services
Revenue
15%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Specialty Diagnostics
Specialty diagnostics (immunodiagnostics, microbiology, transplant diagnostics) and related consumables
Revenue
9.9%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Laboratory Products and Biopharma Services
Laboratory supplies distribution/market channel plus outsourced biopharma services (CDMO/CRO)
Revenue
55.5%
Structure
Competitive
Pricing
moderate
Share
—
Peers
Moat Claims
Life Sciences Solutions
Life science research tools and bioprocessing consumables/instruments
Q2 2026 revenue share is $2,355m / $11,994m and operating-profit share is $1,041m / $2,735m. The segment includes the September 2025 Solventum filtration acquisition. No sufficiently complete product-market denominator supports a share or HHI.
Installed Base Consumables
Demand
Installed Base Consumables
Strength
Durability
Confidence
Evidence
Genetic-sciences instruments pair with related reagents, while single-use bioproduction workflows create recurring consumable demand. The filing does not quantify installed base, proprietary attach rate, or customer switching behavior, so the score is moderate.
Installed Base Consumables moat: definition, examples, and stocks
Erosion risks
- Protocol standardization on open reagents reduces consumables differentiation
- Pricing pressure as competitors bundle similar bioprocessing consumables
- Funding cycles (NIH/academia) and biopharma demand volatility
Leading indicators
- Consumables mix vs instruments mix
- Attach rate of proprietary reagents/kits to installed base
- Gross margin trend in Life Sciences Solutions
Counterarguments
- Many workflows can be multi-sourced (reagents and plastics) with limited switching cost
- Large customers can negotiate aggressively using dual sourcing
Analytical Instruments
Analytical instruments (chromatography, mass spectrometry, electron microscopy) with consumables and services
Q2 2026 revenue share is $1,799m / $11,994m and operating-profit share is $424m / $2,735m. Two proteomics-software acquisitions were added in 2026. No complete analytical-instrument denominator supports a market share or HHI.
Installed Base Consumables
Demand
Installed Base Consumables
Strength
Durability
Confidence
Evidence
Instruments can pull through supporting consumables, software and services, but Thermo Fisher does not disclose segment installed-base size, attach rates, service renewal, or third-party compatibility.
Installed Base Consumables moat: definition, examples, and stocks
Erosion risks
- Third-party consumables and service providers reduce capture of aftermarket revenue
- Technology shifts can shorten instrument replacement cycles
Leading indicators
- Service and consumables revenue as a % of Analytical Instruments revenue
- Service contract renewal rates
Counterarguments
- Customers can standardize on open consumables and multi-vendor service where feasible
Specialty Diagnostics
Specialty diagnostics (immunodiagnostics, microbiology, transplant diagnostics) and related consumables
Q2 2026 revenue share is $1,188m / $11,994m and operating-profit share is $334m / $2,735m. The mix still includes microbiology, which Thermo Fisher agreed to sell to Astorg for about $1.075bn with a third-quarter closing expected. No complete diagnostics denominator supports share or HHI.
Installed Base Consumables
Demand
Installed Base Consumables
Strength
Durability
Confidence
Evidence
Complete blood-test systems and instrument-linked kits and reagents can create recurring pull-through after workflow validation, but the filing does not quantify placements, attach rates, or customer switching.
Installed Base Consumables moat: definition, examples, and stocks
Erosion risks
- Hospital and lab consolidation increases buyer bargaining power
- Rapid innovation cycles can displace assay menus
- Potential portfolio changes (divestitures) can alter scale advantages
Leading indicators
- Installed base and reagent pull-through growth (if disclosed)
- Regulatory warning letters or major quality events
Counterarguments
- Large IVD players can match menu breadth and compete aggressively on price
Laboratory Products and Biopharma Services
Laboratory supplies distribution/market channel plus outsourced biopharma services (CDMO/CRO)
Q2 2026 revenue share is $6,652m / $11,994m and operating-profit share is $936m / $2,735m. Results include Clario from its March 24 acquisition; the $9.098bn preliminary purchase price included $5.934bn of goodwill. No complete mixed distribution/CRO/CDMO denominator supports a share or HHI.
Distribution Control
Supply
Distribution Control
Strength
Durability
Confidence
Evidence
Large lab distribution platform with broad catalog and services creates one-stop procurement convenience and embeds Thermo Fisher in customer supply chains.
Distribution Control moat: definition, examples, and stocks
Erosion risks
- Disintermediation via manufacturer-direct and e-procurement marketplaces
- Large customers shifting to multi-vendor frameworks to force price competition
Leading indicators
- E-commerce penetration and digital procurement adoption
- Gross margin trend in Laboratory Products and Biopharma Services
Counterarguments
- Competitors with scale (e.g., Avantor/VWR) can offer similar catalog breadth and logistics
Procurement Inertia
Demand
Procurement Inertia
Strength
Durability
Confidence
Evidence
Product standardization and supply-chain-management services reduce procurement friction, increasing switching costs for enterprise customers.
Procurement Inertia moat: definition, examples, and stocks
Erosion risks
- Procurement organizations push periodic re-bids and standardize across vendors
- Digital marketplaces lower switching friction
Leading indicators
- Customer retention/renewal of supply agreements (if disclosed)
- Share of wallet with enterprise accounts
Counterarguments
- Switching distributors can be managed during contract re-bids; inertia may be limited
Evidence
Our genetic sciences business combines a wide variety of instruments and related reagents
Directly supports instrument-and-reagent pairing, though not an exclusive format.
a suite of single-use solutions spanning the biologics workflow
Supports recurring consumable demand across bioproduction steps.
a broad offering of instruments and the supporting consumables, software and services
Directly describes the instrument-plus-aftermarket model without quantifying lock-in.
offers a wide range of diagnostic test kits, reagents, culture media, instruments and associated products
Supports the instrument-and-consumables model without establishing exclusivity.
offers virtually everything needed for the laboratory
Supports breadth/one-stop-shop distribution positioning.
Showing 5 of 7 sources.
Risks & Indicators
Erosion risks
- Protocol standardization on open reagents reduces consumables differentiation
- Pricing pressure as competitors bundle similar bioprocessing consumables
- Funding cycles (NIH/academia) and biopharma demand volatility
- Third-party consumables and service providers reduce capture of aftermarket revenue
- Technology shifts can shorten instrument replacement cycles
- Hospital and lab consolidation increases buyer bargaining power
Leading indicators
- Consumables mix vs instruments mix
- Attach rate of proprietary reagents/kits to installed base
- Gross margin trend in Life Sciences Solutions
- Service and consumables revenue as a % of Analytical Instruments revenue
- Service contract renewal rates
- Installed base and reagent pull-through growth (if disclosed)
Research TMO elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.